Factors Associated With Mortality in US Adults With NAFLD

November 8-12, 2019; Boston, Massachusetts
Presence of advanced hepatic fibrosis, CKD, and elevated cardiac risk score increase risk of mortality in all patients with NAFLD, regardless of BMI.
Format: Microsoft PowerPoint (.ppt)
File Size: 277 KB
Released: November 16, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Related Content

Unlocked slides from Giada Sebastiani, MD and CCO: Role of diet, exercise, and current treatments for NASH

person default Giada Sebastiani, MD Released: June 2, 2021

Expert advice on current NAFLD/NASH treatments: Mediterranean diet, vitamin E, pioglitazone, GLP-RAs, eg semaglutide. From Clinical Care Options (CCO)

person default Giada Sebastiani, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: June 2, 2021 Expired: June 1, 2022

Unlocked slides from Wing-Kin Syn, MBChB, PhD, FACP, FRCP and CCO: How to use biomarkers and imaging to evaluate NAFLD and NASH—ruling in or out hepatic fibrosis

Wing-Kin Syn, MBChB, PhD, FACP, FRCP Released: April 27, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue